Vor Biopharma Inc. has announced a public offering of $100 million of its common stock, with a possible additional $15 million. J.P. Morgan, Jefferies, Citigroup, and TD Cowen are the joint book-running managers for the offering. The shares are being offered pursuant to a registration statement filed with the SEC. The offering is subject to market conditions and completion is not guaranteed. Vor Bio is focused on advancing telitacicept, a dual-target fusion protein, to treat autoimmune diseases. The company’s forward-looking statements are subject to risks and uncertainties, with factors that could impact the offering’s success.

Read more at GlobeNewswire: Vor Bio Announces Proposed Public Offering of $100 Million